Syneos Health to Present at Upcoming Investor Conferences
Syneos Health (Nasdaq:SYNH) announced upcoming presentations at two investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syneos Health (Nasdaq:SYNH) announced upcoming presentations at two investor conferences. CEO Alistair Macdonald will speak at the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 a.m. GMT. CFO Jason Meggs is scheduled to present at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 4:20 p.m. ET. Webcasts will be available on the Company’s Investor Relations website for both events.
Details
News Market Reaction – SYNH
The recorded move for SYNH in the trading session of this news was +2.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that the Company is scheduled to present at two upcoming investor conferences:
- Chief Executive Officer Alistair Macdonald is scheduled to present at the Jefferies London Healthcare Conference on November 18, 202, at 8:00 a.m. GMT
- Chief Financial Officer Jason Meggs is scheduled to present at the Evercore ISI 4th Annual HealthCONx Conference December 1, 2021, at 4:20 p.m. ET
A webcast of each event, along with an archived audio replay of each presentation, will be available on the Company’s Investor Relations website at investor.syneoshealth.com.
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 28,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
| Investor Relations Contact: | Press/Media Contact: |
| Ronnie Speight | Gary Gatyas |
| Senior Vice President, Investor Relations | Executive Director, External Communications |
| +1 919 745 2745 | +1 908 763 3428 |
| Investor.Relations@syneoshealth.com | gary.gatyas@syneoshealth.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.